Top 5 Articles About Weight-Loss Drugs in 2023
Weight-loss medications were very much in the news this year, and the pages and website of Managed Healthcare Executive were no exception. Articles on off-label use of the GLP-1s such as Ozempic (semaglutide) and the FDA approval of Zepbound (tirzepatide) garnered the most page views.
For Weight Loss, Off-Label GLP-1s Are Increasingly the Chosen Ones | AMCP 2023
They are the trendy way to lose weight, and payers have been noticing an increase in GLP-1 claims. An analysis of the pharmacy and healthcare claims of a small commercial health plan in Texas documents the growth in the off-label usage of the GLP-1s, such as Ozempic, for weight loss.
Coping With the Ozempic-Wegovy-Mounjaro Tsunami
Insurers are using prior authorization and other managed care strategies to control costs associated with the growing number of prescriptions, on- and off-label, for the weight-loss medications.
Trial Investigates Weight Loss Drug for Patients with Heart Failure
Patients with heart failure and obesity who were administered semaglutide experienced better results — they reported fewer symptoms, felt less physically limited, lost more weight, and could walk longer in a 6-minute test.
FDA Approves Zepbound, New Weight Loss Drug
Tirzepatide, with the brand name Zepbound, is expected to be available by the end of the year in six doses at a list price of $1,059.87, which is about 20% lower than semaglutide.
How Prime Therapeutics Tugged on the Reins of the Galloping GLP-1 Spend | AMCP Nexus 2023
The Minnesota-based pharmacy benefit manager says a program that resulted in patients switching from two incretin therapy prescriptions to one yielded $7,500 in savings per patient and a total of $3.5 million.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
